At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 339 enrolled
Drug / intervention
Duloxetine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Eight-week, Randomized, Double-blind, Two Parallel Groups, Study to Assess Clinical Response of Duloxetine 60 mg and 120 mg Per Day in Patients Hospitalized for Severe Depression
In Brief
A Phase 4 clinical trial evaluating Duloxetine and Placebo for Depressive Disorder, Major. Completed, enrolled 339 participants.
Detailed Summary
Study to assess efficacy of Duloxetine 120 mg and Duloxetine 60 mg in patients hospitalized for severe depression after 4 weeks of treatment. To evaluate the rescue option in non-responding patients. Safety of Duloxetine will also be assessed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
Primary CompletionAug 2008
First PostedSep 2014
TodayJul 2026
First PostedSep 1, 2014
Enrollment StartFeb 9, 2007
Primary CompletionAug 26, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.8 years ago
Interventions
Duloxetinedrug
Capsule
Placebodrug
Capsule